Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
OwnerMustapha CHADJAA, Phillip DENNISinventors
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a combination of (i) an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) a VEGFR-2 inhibitor, and (iii) an anti-PD-1 antibody or anti-PD-L1 antibody, for use in the treatment of a cancer.
Claims28
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a combination of (i) an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) a VEGFR-2 inhibitor, and (iii) an anti-PD-1 antibody or anti-PD-L1 antibody.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising (i) an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) a VEGFR-2 inhibitor, (iii) an anti-PD-1 antibody or an anti-PD-L1 antibody, and a pharmaceutically acceptable excipient.
A kit comprising (i) a pharmaceutical composition comprising an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, and a pharmaceutically acceptable excipient, (ii) a pharmaceutical composition comprising a VEGFR-2 inhibitor and a pharmaceutically acceptable excipient, and (iii) a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody and a pharmaceutically acceptable excipient.
(canceled)
(canceled)
Dependencies are inferred from the claim text.